Oritavancin (Orbactiv)

INTRODUCTION The resistance of gram-positive pathogens to currently available antibiotics has increased at an alarming rate, while the development of new effective agents has not kept pace.1 In response to this critical global concern, the Generating Antibiotic Incentives Now Act, part of the Food and Drug Administration Safety and Innovation Act, was signed into law in July 2012 to expedite the development of antibacterials.1 Under this legislation, oritavancin (Orbactiv, The Medicines Company) was designated as a qualifi ed infectious disease product and given priority review by the Food and Drug Administration (FDA).1 It received FDA approval in 2014. Oritavancin is a new-generation lipoglycopeptide indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible organisms, including Staphy­ lococcus aureus (methicillin-susceptible DRUG FORECAST